Adverse drug reactions among inpatients in a north Indian referral hospital

National Medical Journal of India

Volumn 13, Issue 1, 2000, Pages 16-18

  Uppal, R ^a   Jhaj, R ^a   Malhotra, S ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; AYURVEDIC DRUG; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CIPROFLOXACIN; CONTRAST MEDIUM; COTRIMOXAZOLE; IOTALAMATE SODIUM; LITHIUM; MEGLUMINE DIATRIZOATE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANTICONVULSANT THERAPY; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHILD; CONTRAST ENHANCEMENT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHILD; DRUG THERAPY; FEMALE; HUMANS; INCIDENCE; INDIA; MALE; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 0034021866     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. World Health Organization. International drug monitoring: The role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser 1972;498: 1-25.
2. Rawlins MD. Spontaneous reporting of adverse drug reactions F: The data. Br J Clin Pharmacol 1988;26:1-5.
3. Karch FE, Lasagna L. Adverse drug reactions - A matter of opinion. Clin Pharmacol Ther 1976;19:489-92.
4. Rawlins MD. Spontaneous reporting of adverse drug reactions II: Uses. Br J Clin Pharmacol 1988;26:7-11.
5. Davis DM. Textbook of adverse drug reactions. New York:Oxford University Press, 1985.
6. Bem JL, Mann RD, Rawlins MD. Review of yellow cards - 1986 and 1987. BMJ 1988;296:1319.
7. Dharnidharka VR, Kandoth PN, Anand RK. Adverse drug reactions in pediatrics with a study of in-hospital intensive surveillance. Indian Pediatr 1993;30:745-50.
8. Cirko-Begovic A, Vrhovac B, Bakran I. Intensive monitoring of adverse drug reactions in infants and preschool children. Eur J Clin Pharmacol 1989;36:63-5.
9. World Health Organization. Drugs as risk factors in severe cutaneous diseases. WHO Drug Information 1996;10:33.
10. Rohrer TE, Ahmed AR. Toxic epidermal necrolysis. Int J Dermatol 1991;30: 457-66.
11. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
12. World Health Organization. Mucocutaneous reactions and carbamazepine. WHO Drug Information 1997;11:20.
13. Askmark H, Wilholm BE. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990;81:131-40.
14. Leape LL, Brennan TA, Laird N, Lawthers AG, Lacalio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients: Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.
15. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.Am Rev Respir Dis 1978;18: 461-6.
16. Dossing M, Wilcke JTR, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: An 11-year study. Tuber Lung Dis 1996;77:335-40.
17. Behrman RE, Kliegman RM, Arvin AM (eds). Nelson's Textbook of Pediatrics. Bangalore:WB Saunders, 1996.